Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer - Trial NCT06395844
Access comprehensive clinical trial information for NCT06395844 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Anhui Provincial Cancer Hospital and is currently Recruiting. The study focuses on Ovarian Cancer. Target enrollment is 28 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Anhui Provincial Cancer Hospital
Timeline & Enrollment
Phase 1/2
May 01, 2024
Dec 31, 2026
Primary Outcome
R0 resection rate
Summary
The goal of this type of clinical trial study is to evaluate the safety and efficacy of
 metabolic remodeling nature killer cells as neoadjuvant therapy in newly diagnosed patients
 with advanced ovarian cancer
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06395844
Non-Device Trial